financetom
Business
financetom
/
Business
/
Williams-Sonoma Likely to Issue Cautious 2025 Outlook Amid Softening Demand Trends, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Williams-Sonoma Likely to Issue Cautious 2025 Outlook Amid Softening Demand Trends, Wedbush Says
Feb 28, 2025 6:51 AM

09:16 AM EST, 02/28/2025 (MT Newswires) -- Williams-Sonoma ( WSM ) is expected to issue a cautious 2025 outlook when it reports fourth-quarter results next month amid softening demand trends for home furnishings goods, Wedbush Securities said in a Friday client note.

The key factors driving demand for furniture and home furnishing products have waned or remained soft into early 2025 despite a rebound in activity in the fourth quarter, according to the brokerage. US President Donald Trump's tariff plan has also weighed on consumer sentiment but its final impact on discretionary spending and inflation is "difficult to forecast," Wedbush said.

Williams-Sonoma ( WSM ) usually provides conservative guidance and this trend will likely continue amid macroeconomic and industry uncertainties, according to the brokerage. Wedbush said the home goods retailer could provide a comparable sales outlook ranging from a 1% decline to a 2% increase for fiscal 2025. Wedbush now estimates the metric at a 1.2% increase, down from its previous forecast for a 1.5% rise.

The brokerage sees limited chances for the retailer to expand margins this year that aren't volume-related as it believes margin tailwinds from the past five years have subsided. Additionally, new product launches may improve Williams-Sonoma's ( WSM ) market share only incrementally, Wedbush said.

"We brace for a cautious guide that could disappoint investors," Wedbush analysts Seth Basham and Matthew McCartney wrote in the note.

Wedbush now expects Williams-Sonoma ( WSM ) to record fiscal fourth-quarter earnings of $3.13 per share, up from its previous estimate of $2.93. The brokerage forecasts the retailer to log flat comparable sales growth in the quarter, compared with its prior expectation for a 4.1% decline. The current consensus on FactSet is for non-GAAP EPS of $2.92 and a 1.7% decline in same-store sales.

"Williams-Sonoma ( WSM ) should be a bigger beneficiary of improved category demand trends in (the fourth quarter) than other publicly traded peers who are more focused on furniture," according to Basham and McCartney.

Wedbush maintained its neutral rating on Williams-Sonoma's ( WSM ) stock and lifted its 12-month price target to $190 from $175.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Blue Owl Capital in Talks to Acquire IPI Partners for $1 Billion, Bloomberg Reports
--Blue Owl Capital in Talks to Acquire IPI Partners for $1 Billion, Bloomberg Reports
Oct 3, 2024
12:30 PM EDT, 10/03/2024 (MT Newswires) -- Price: 19.90, Change: +0.20, Percent Change: +1.02 ...
Itron Insider Sold Shares Worth $3,930,998, According to a Recent SEC Filing
Itron Insider Sold Shares Worth $3,930,998, According to a Recent SEC Filing
Oct 3, 2024
12:30 PM EDT, 10/03/2024 (MT Newswires) -- Thomas Deitrich, Director, President & CEO, on October 01, 2024, sold 37,500 shares in Itron ( ITRI ) for $3,930,998. Following the Form 4 filing with the SEC, Deitrich has control over a total of 230,276 shares of the company, with 205,276 shares held directly and 25,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/780571/000112760224025027/xslF345X05/form4.xml Price:...
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
Oct 3, 2024
12:37 PM EDT, 10/03/2024 (MT Newswires) -- Eli Lilly ( LLY ) , CVS's (CVS) pharmacy unit and other drug companies and pharmacy benefit managers have been sued by Texas Attorney General Ken Paxton for allegedly inflating insulin prices, Paxton's office said Thursday. Paxton accused the major insulin manufacturers of artificially and willingly raising prices and then paying pharmacy benefit...
Market Chatter: Helix Energy Mulls Strategic Options, Including Sale
Market Chatter: Helix Energy Mulls Strategic Options, Including Sale
Oct 3, 2024
12:32 PM EDT, 10/03/2024 (MT Newswires) -- Helix Energy (HLX) is considering various strategic options, including the possibility of a sale, Bloomberg reported Thursday, citing people familiar with the matter. The company is working with advisers to gauge potential buyer interest, according to the people. Discussions are reportedly still in early stages and there is no certainty that Helix Energy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved